These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 17764544)

  • 1. High resolution melting for mutation scanning of TP53 exons 5-8.
    Krypuy M; Ahmed AA; Etemadmoghadam D; Hyland SJ; ; DeFazio A; Fox SB; Brenton JD; Bowtell DD; Dobrovic A
    BMC Cancer; 2007 Aug; 7():168. PubMed ID: 17764544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling.
    Bastien R; Lewis TB; Hawkes JE; Quackenbush JF; Robbins TC; Palazzo J; Perou CM; Bernard PS
    Hum Mutat; 2008 May; 29(5):757-64. PubMed ID: 18348286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation scanning of exon 20 of the BRCA1 gene by high-resolution melting curve analysis.
    Vorkas PA; Christopoulos K; Kroupis C; Lianidou ES
    Clin Biochem; 2010 Jan; 43(1-2):178-85. PubMed ID: 19747471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing high-resolution melt curve analysis for accurate detection of gene variants in complex DNA fragments.
    Tindall EA; Petersen DC; Woodbridge P; Schipany K; Hayes VM
    Hum Mutat; 2009 Jun; 30(6):876-83. PubMed ID: 19280649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High sensitivity of detection of TP53 somatic mutations by fluorescence-assisted mismatch analysis.
    Tessitore A; Di Rocco ZC; Cannita K; Ricevuto E; Toniato E; Tosi M; Ficorella C; Frati L; Gulino A; Marchetti P; Martinotti S
    Genes Chromosomes Cancer; 2002 Sep; 35(1):86-91. PubMed ID: 12203794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DMSO Increases Mutation Scanning Detection Sensitivity of High-Resolution Melting in Clinical Samples.
    Song C; Castellanos-Rizaldos E; Bejar R; Ebert BL; Makrigiorgos GM
    Clin Chem; 2015 Nov; 61(11):1354-62. PubMed ID: 26432802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffin-embedded tissue.
    Fadhil W; Ibrahem S; Seth R; Ilyas M
    J Clin Pathol; 2010 Feb; 63(2):134-40. PubMed ID: 20154035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
    Liu Y; Bodmer WF
    Proc Natl Acad Sci U S A; 2006 Jan; 103(4):976-81. PubMed ID: 16418264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations.
    Milbury CA; Li J; Makrigiorgos GM
    Clin Chem; 2009 Dec; 55(12):2130-43. PubMed ID: 19815609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
    Ecke TH; Lenk SV; Schlechte HH; Loening SA
    Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic strategy for analytical scanning of BRCA1 gene by fluorescence-assisted mismatch analysis using large, bifluorescently labeled amplicons.
    Ricevuto E; Sobol H; Stoppa-Lyonnet D; Gulino A; Marchetti P; Ficorella C; Martinotti S; Meo T; Tosi M
    Clin Cancer Res; 2001 Jun; 7(6):1638-46. PubMed ID: 11410501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
    Hosny G; Farahat N; Hainaut P
    Cancer Lett; 2009 Mar; 275(2):234-9. PubMed ID: 19046801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
    Lianidou ES; Levesque MA; Katsaros D; Angelopoulou K; Yu H; Genta F; Arisio R; Massobrio M; Bharaj B; Diamandis EP
    Anticancer Res; 1999; 19(1B):749-56. PubMed ID: 10216487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
    Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
    Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
    Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of p53 protein in pterygia is not accompanied by TP53 gene mutation.
    Schneider BG; John-Aryankalayil M; Rowsey JJ; Dushku N; Reid TW
    Exp Eye Res; 2006 Jan; 82(1):91-8. PubMed ID: 16005868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 gene in blood plasma DNA of tumor patients.
    Schlechte HH; Stelzer C; Weickmann S; Fleischhacker M; Schulze G
    Ann N Y Acad Sci; 2004 Jun; 1022():61-9. PubMed ID: 15251941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of high-resolution melting analysis with denaturing high-performance liquid chromatography for mutation scanning: cystic fibrosis transmembrane conductance regulator gene as a model.
    Chou LS; Lyon E; Wittwer CT
    Am J Clin Pathol; 2005 Sep; 124(3):330-8. PubMed ID: 16191501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.